Skip to main content
Veterinary Medicines

Feligen CRP vakcina A.U.V.

Authorised
  • Feline panleucopenia virus, strain Snow Leopard, Live
  • Feline calicivirus, strain F9, Live
  • Feline rhinotracheitis virus, strain F2, Live

Product identification

Medicine name:
Feligen CRP vakcina A.U.V.
Active substance:
  • Feline panleucopenia virus, strain Snow Leopard, Live
  • Feline calicivirus, strain F9, Live
  • Feline rhinotracheitis virus, strain F2, Live
Target species:
  • Cat
Route of administration:
  • Intramuscular use
  • Subcutaneous use

Product details

Active substance and strength:
  • Feline panleucopenia virus, strain Snow Leopard, Live
    3.70
    log10 tissue culture infective dose 50
    /
    1.00
    unit(s)/dose
  • Feline calicivirus, strain F9, Live
    4.60
    log10 tissue culture infective dose 50
    /
    1.00
    unit(s)/dose
  • Feline rhinotracheitis virus, strain F2, Live
    5.00
    log10 tissue culture infective dose 50
    /
    1.00
    unit(s)/dose
Pharmaceutical form:
  • Powder and solvent for suspension for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Cat
  • Subcutaneous use
    • Cat
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI06AD04
Authorisation status:
  • Valid
Authorised in:
  • Hungary
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Virbac
Marketing authorisation date:
Manufacturing sites for batch release:
  • VIRBAC
Responsible authority:
  • Directorate Of Veterinary Medicinal Products
Authorisation number:
This information is not available for this product.
Date of authorisation status change:
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."